BMS Reports P-III Trial (CheckMate -77T) Results of Neoadjuvant Opdivo (nivolumab) + CT for Resectable Non-Small Cell Lung Cancer
Shots:
- The P-III trial evaluating neoadjuvant Opdivo + CT vs CT + PBO in 452 patients with resectable stage IIA to IIIB NSCLC
- The trial met its 1EPs of improved EFS as assessed by BICR & the safety profile was consistent with prior reported studies in NSCLC. The company will share the results with the scientific community at an upcoming medical conference as well as discussing with health authorities
- Opdivo, a PD-1 immune checkpoint inhibitor is currently approved in 65+ countries, incl. the US, EU, Japan & China. Opdivo and Opdivo-based combinations showed improved efficacy in the neoadjuvant, adjuvant, or perioperative treatment of 4 tumor typesz
Ref: Businesswire | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
